.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,692,006

« Back to Dashboard

Details for Patent: 7,692,006

Title:Phthalazinone derivatives
Abstract: 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one as crystalline Form A.
Inventor(s): Menear; Keith Allan (Cambridge, GB), Ottridge; Anthony Peter (Cambridge, GB), Londesbrough; Derek John (Sunderland, GB), Hallett; Michael Raymond (Sunderland, GB), Mulholland; Keith Raymond (Macclesfield, GB), Pittam; John David (Macclesfield, GB), Laffan; David Dermot Patrick (Macclesfield, GB), Ashworth; Ian Woodward (Macclesfield, GB), Jones; Martin Francis (Macclesfield, GB), Cherryman; Janette Helen (Macclesfield, GB)
Assignee: Kudos Pharmaceuticals Limited (London, GB)
Filing Date:Oct 17, 2007
Application Number:11/873,671
Claims:1. A method of obtaining 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one (compound A) as crystalline Form A comprising the steps of: (i) crystallising 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one from a solvent; (ii) if the original solvent is not ethanol, treating the crystalline compound A with ethanol; (iii) treating the crystalline compound A containing trapped ethanol obtained from either step (i) or step (ii) with water to remove trapped ethanol; (iv) drying the resulting product.

2. A method of obtaining 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one (compound A) as crystalline Form A comprising the steps of: (i) crystallising 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one from a solvent; (ii) if the original solvent used in the synthesis of compound A in the crystalline form is not a mixture of water and a C.sub.1-2 alcohol, heating the compound with a mixture of water and a C.sub.1-2 alcohol; (iii) distilling the mixture from step (ii) at ambient pressure; and (iv) drying the resulting product from step (iii).

3. A method of obtaining 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one (compound A) as crystalline Form A comprising the steps of: (i) suspending compound A in a mixture of water and a C.sub.1-2 alcohol as the solvent; (ii) heating the suspension from step (i) to reflux; (iii) cooling the solution from step (ii) and seeding with compound A as Form A; (iv) drying the resulting product from step (iii).

4. A method of synthesising 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one from 4-[4-fluoro-3-(piperazine-1-carbonyl)-benzyl]-2H-phthalazin-1-One comprising the step of: (i) adding a pre-mixed solution of triethylamine and cyclopropane carbonyl chloride, in an organic solvent, to 4-[4-fluoro-3-(piperazine-1-carbonyl)-benzyl]-2H-phthalazin-1-one in the same organic solvent with the temperature of the solution being controlled to be below 2000.

5. A method synthesising 2-fluoro-5-(4-oxo-3,4-dihydro-phthalazin-1-ylmethyl)-benzoic acid, comprising the step of: (i) synthesising diethyl (3-oxo-1,3-dihydro-2-benzofuran-1-yl)phosphonate from 2-carboxybenzaldehyde by reaction with the sodium salt of diethyl phosphite, followed by reaction with methanesulphonic acid; (ii) synthesising 2-fluoro-5-[(E/Z)-(3-oxo-2-benzofuran-1(3H)-ylidene)methyl]benzonitrile from diethyl (3-oxo-1,3-dihydro-2-benzofuran-1-yl)phosphonate, by reaction with triethylamine in 2-methyltetrahydrofuran.

6. The method of claim 5, further comprising the step of: (i) synthesising 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzonitrile (ED): ##STR00014## from compound E: ##STR00015## by reaction with hydrazine hydrate; and (ii) synthesising compound D: ##STR00016## from compound ED by reaction with sodium hydroxide.

7. 2-Fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzonitrile (ED): ##STR00017##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc